We have begun work on KB104 – a treatment for Netherton Syndrome (https://ghr.nlm.nih.gov/condition/netherton-syndrome) that is a skin barrier defect with constant and recurring allergic manifestations, caused by mutations in the SPINK5 gene. There are no treatments available for the underlying disease. Systemic treatment with TNF-antagonists and immunoglobins to counteract the immunological deficiencies provides relief but carries the burden of severe side effects. Restoration of functional Spink5 using ex-vivo gene modified approaches have shown benefit in preclinical studies but are hard to commercialize. We believe that direct delivery of Spink5 using our optimized HSV platform could provide an attractive off-the-shelf solution for this debilitating disease.